TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hutchmed
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

HUTCHMED introduced its Antibody-Targeted Therapy Conjugate (ATTC) platform, focusing on a novel approach to cancer treatment using targeted therapies with dual mechanisms of action. The lead candidate HMPL-A251 demonstrates promising preclinical efficacy in targeting HER2-positive tumors with improved safety profiles.

Insights
HCM   positive

Company showcased breakthrough research in cancer treatment with innovative ATTC platform, demonstrated promising preclinical results, and outlined clear development strategy for lead candidate HMPL-A251